Abionyx Pharma's Stock Plummets 8.5% Following Capital Increase
The Toulouse-based biotech suffers a heavy stock market penalty on Thursday morning, the day it finalized its capital increase. The stock is among the biggest losers on the Paris stock exchange, in an otherwise positively oriented market. The dilution related to the financing operation is clearly weighing on the valuation.
Stock Plunges 8.56% to €2.35 After Successful €18.7 Million Capital Raise
Abionyx Pharma's stock loses 8.56% at €2.35 mid-morning, while the CAC 40 is up 0.45% and the SBF 120 advances by 0.39%. The French biopharmaceutical company announced this Thursday the successful completion of its capital increase of 18.7 million euros, accompanied by the submission of a notice of drawdown for a first tranche of 10 million euros in bonds with Danish fund Fenja Capital. The operation, which had a subscription price set at €2.65 per share at its launch on May 27, aims to finance clinical programs in sepsis and regulatory advancements in LCAT deficiency.
The current price is now 11% below this subscription price, reflecting the market-integrated dilution. The stock is among the steepest declines in the CAC All Shares this morning, even as the overall dynamics of the Parisian market are positive.
A Decline that Extends a Fundamental Slide and Breaks Key Support at €2.54
The previous session had already seen the stock break its support at €2.54, dropping to a low of €2.51, before closing above at €2.57. Thursday's movement confirms the break, with the price firmly settling below this technical threshold. The situation remains degraded: the stock is trading 18.69% below its MM20 (€2.89) and more than 34% below its MM200 (€3.60), while the RSI drops to 25, into a marked oversold zone.
Over three months, the decline reaches 29.44%, while the performance over one year remains positive (+90.28%), a remnant of the late 2025 rally. The loss of 12.38% over the week reflects the acceleration of the decline; the company had announced the financing operation at the end of May. With the price now distant from all its moving averages and a broken reference support, the next observation zone is around the recent lows of €2.51.
